Article of manufacture comprising aflibercept or 2IV aflibercept

摘要

Requirement 1: include (a) packaging materials, (b) polymerized peptide of No. 1 SEQ or biocide of No. 1 SEQ and (c) labels or instructions in No. 1 SEQ package, including labels, to explain to potential users: polymerized peptide or its biocide, Patients with severe bleeding should not be treated, the treatment of patients with gastrointestinal perforation should be stopped, and / or the treatment should be stopped for patients with severe trauma. Requirement 10: a method to promote the use of SEQ ID 1 polypeptide,Or a biological agent, including a method, at least at the stage of transmitting a specific group information in a container, the group information includes: (a) polypeptide or its biological agent should not be given to patients with severe bleeding; and (or) (b) polypeptide or its biological agent should be stopped at the time of patient trial. Gastrointestinal perforation and / or (c) polypeptides or their biological agents must be stopped in patients with damage. Requirement 11: treatment of cancer or cancer symptoms in patients in needUnderstand that this method is effective for the treatment of patients, and the dosage is equivalent to a polypeptide of SEQ ID 1, or a biological agent of this polypeptide. In this case, (a) polypeptide should not be applied to patients with severe bleeding, or the polypeptide should be bioassayed, and (b) polypeptide should be applied, or the polypeptide should be bioassayed, Treatment of patients with gastrointestinal perforation should be discontinued, and / or (c) polypeptides or bioassays of patients with severe injury should be discontinued. Requirement 12: method of treatment for colorectal cancer (CRC) in patients who need to treat symptoms of colorectal cancer or colorectal cancer,This method includes effective treatment of patients from a polypeptide of SEQ ID 1, or from biopharmaceuticals of SEQ ID 1, folic acid, 5-fluoro (5-FU) and irinotecan, in which: (a) polypeptide or its biopharmaceuticals should not be applied to patients with severe bleeding; and / or (b) polypeptide, or For patients with gastrointestinal perforation, bioimilar of this drug should be stopped; and (or) (c) for patients with serious injury, polypeptide or bioimilar of this drug should be stopped. Claim 31: polypeptide of SEQ ID 1, or biological agent of SEQ ID 1,For the treatment of cancer patients or cancer symptoms, in which case: (a) polypeptides or their biological agents should not be administered to patients with severe bleeding, and (or) (b) polypeptides or their biological agents should not be administered to patients with gastrointestinal perforation; and (or) (c) polypeptides, Or biological agents, which must be stopped in patients with severe injuries 13. Claim 33: a polypeptide containing SEQ ID No. 1 or an effective therapeutic amount of its biological imilar combined with folk acid,5-fluoro (5-FU) and irinoten, including a drug acceptable vehicle for the treatment of patients with rectal cancer or rectal cancer symptoms (CRC), wherein: (a) polypeptides or their biological agents should not be administered to patients with severe bleeding; and / or (b) polypeptides, Alternatively, patients with gastrointestinal perforation must stop taking the drug, and / or (c) polypeptides, or bioassays must stop taking the drug.